Skip to main content

Pharma News

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Biocon Biologics has secured multiple market access agreements for biosimilar to Stelara

    Biocon Biologics Ltd , a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access agreements for Yesintek™, its biosimilar to Stelara®. The market access agreements from numerous plans represent over 100+ million lives in the United States.
  • Novartis to acquire Regulus Therapeutics and farabursen
    Novartis announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus’ lead asset, farabursen.
  • Largest Osteoarthritis Genetic Study Uncovers Pathways to New Therapies and Repurposed Drugs
    Researchers have uncovered multiple new genes and genetic pathways that could lead to repurposing hundreds of existing drugs for osteoarthritis, the most common form of arthritis. The research, which analyzed data from nearly 2 million people in diverse populations worldwide, was recently published in Nature. It represents an extensive genetic exploration of osteoarthritis, a condition affecting over 600 million people globally.
  • Long-term survival rates of some Acute Myeloid Leukaemia patients could double with sensitive bone marrow test
    A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukaemia by helping doctors identify if they might relapse up to three months earlier. The patient-specific molecular test can detect low levels of leukaemia cells in the body, known as minimal residual disease, which when left untreated causes the disease to relapse.
  • India has to wait for Sanofi Meningitis vaccine
    Sanofi Healthcare India has submitted the application for grant of permission to import Meningococcal vaccine but the subject expert committee of CDSCO requires further information to grant permission.
  • In-Cosmetics, Global held in Amsterdam, Nederlands

    In-Cosmetics Global, the world’s largest conference and exhibition for the cosmetics industry took place from 8th to 10th April 2025 in Amsterdam at RAI Exhibition Center. In-Cosmetics Global is truly, well, global as the event had most of the world’s top personal care ingredient suppliers as well as niche companies making waves in the industry.

    Attendees were from all over the world. Europe accounted to almost 60% of attendees, followed by Asia Pacific, South Central America, and North America and Middle East & Africa.

  • Human Mixtard penfill to be replaced with injectables, Novo Nordisk clarifies
    Novo Nordisk is now discontinuing its Human Mixtard penfill by the year's end. However Mixtard in India will continue to be available in vials. Along with it, other forms of insulin including human insulin from Novo Nordisk will continue to be available in vials & devices for patients across India.
  • Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052
    Aclaris Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific anti-TSLP/IL-4R monoclonal antibody.
  • A repurposed anti-inflammatory drug may help treat alcohol use disorder and related pain

    A preclinical study from scientists at Scripps Research finds that a drug already FDA-approved for treating inflammatory conditions may help reduce both alcohol intake and pain sensitivity two issues that commonly co-occur with alcohol use disorder (AUD).

  • Empowering antibodies to better activate the immune system
    Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of the immune system, which then go to work to clear an infection. A new study from Scripps Research explores the factors that influence how effectively antibodies engage specific immune cells.
Subscribe to Pharma News